Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).

Weickhardt, Andrew J; Foroudi, Farshad; Lawrentschuk, Nathan; Xie, Jing; Sidhom, Mark; Pal, Abhijit; Grimison, Peter; Zhang, Alison; Ng, Siobhan; Tang, Colin; Hovey, Elizabeth; Chen, Colin; Hruby, George; Guminski, Alexander; McJannett, Margaret; Conduit, Ciara; Tran, Ben; Davis, Ian D; Hayne, Dickon

doi:10.1016/j.euo.2023.09.011

Title

Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).

Publication Date

2023-10-06

Author(s)

Weickhardt, Andrew J

Foroudi, Farshad

Lawrentschuk, Nathan

Xie, Jing

Sidhom, Mark

Pal, Abhijit

Grimison, Peter

Zhang, Alison

Ng, Siobhan

Tang, Colin

Hovey, Elizabeth

Chen, Colin

Hruby, George

Guminski, Alexander

McJannett, Margaret

Conduit, Ciara

Tran, Ben

Davis, Ian D

Hayne, Dickon

Subject

Bladder cancer

Chemoradiation

Immunotherapy

Type of document

Journal Article

OrcId

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1016/j.euo.2023.09.011

Abstract

Radiation may improve the efficacy of immune checkpoint inhibition. This study investigates the combination of pembrolizumab and chemoradiation (CRT) for muscle-invasive bladder cancer (MIBC). To assess the feasibility and safety of pembrolizumab combined with CRT for MIBC. A single-arm phase 2 trial was performed with 28 participants having cT2-T4aN0M0 MIBC (Eastern Cooperative Oncology Group performance status 0-1; estimated glomerular filtration rate ≥40 ml/min; no contraindications to pembrolizumab) suitable for CRT. Whole bladder radiation therapy (RT; 64 Gy in 32 daily fractions, over 6.5 wk, combined with cisplatin (35 mg/m2 intravenously [IV] weekly, six doses) and pembrolizumab (200 mg IV q3 weeks, seven doses), both starting with RT. Surveillance cystoscopy/biopsy and computerised tomography scans performed 12 and 24 wk after CRT. The primary endpoint was feasibility, determined by a prespecified satisfactory low rate of grade 3 or worse nonurinary toxicity or completion of planned CRT according to defined parameters. Secondary endpoints were complete cystoscopic response, locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), and overall survival (OS). Twenty-eight patients were enrolled with a 31-mo median follow-up. Six had Grade >3 nonurinary adverse events during/within 12 wk after treatment; three had more than one cisplatin dose reduction. The 24-wk post-CRT complete response (CR) rate was 88%. Eight patients developed metastatic disease, and three had nonmetastatic progression. The DMFS at 2 yr is 78% (95% confidence interval [CI] 54-90%), with LRPFS at 2 yr of 87% (95% CI 64-96%) and median OS of 39 mo (95% CI 17.1-not evaluable). Limitations are the single-arm design and sample size. Combining pembrolizumab with CRT for MIBC was feasible, with manageable toxicity and promising CR rates. Immunotherapy treats nonmetastatic/metastatic bladder cancer effectively. We combined pembrolizumab with chemotherapy and radiation to assess its safety and impact on treatment delivery. The combination was feasible with encouraging early activity. Further larger trials are warranted.

Link

link

Citation

European Urology Oncology 2023-10-06

Jornal Title

European Urology Oncology

ISSN

2588-9311

Austin Health

Files: